SCHEDULE: NEA Boosts Korro Bio Stake to 9.9% via Private Placement

New Enterprise Associates 17, L.P. and its affiliates increased their beneficial ownership in Korro Bio, Inc. to 9.9% through a recent private placement.

Summary

• New Enterprise Associates 17, L.P. (NEA 17) and its affiliated entities and managers reported beneficial ownership of 1,435,487 shares of Korro Bio, Inc. Common Stock, representing 9.9% of the class.
• This ownership includes 1,297,893 shares of Common Stock and rights to purchase up to 137,594 shares via Pre-Funded Warrants, subject to a 9.99% beneficial ownership limitation.
• Ali Behbahani, one of the managers, also holds options to purchase an additional 21,190 shares, bringing his total beneficial ownership to 1,456,677 shares, also 9.9%.
• The increase in ownership resulted from NEA 17's participation in a private placement that closed on March 10, 2026.
• NEA 17 purchased 207,100 shares of Common Stock at $11.11 per share and Pre-Funded Warrants for 242,945 shares at $11.109 per warrant.
• The funds for this acquisition came from NEA 17's working capital.
• The purpose of the acquisition is for investment.
• A 2026 Registration Rights Agreement was established, granting NEA 17 and other investors certain registration rights for the newly acquired securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting continued institutional investor confidence and a successful capital raise for Korro Bio, Inc. The investment by NEA, a reputable VC firm, is a strong signal, though the filing itself is primarily a disclosure of ownership.

Positives

• Significant investment by a prominent venture capital firm, New Enterprise Associates (NEA), indicating confidence in Korro Bio, Inc.
• NEA 17 acquired shares and warrants in a private placement, suggesting a strategic investment at a specific valuation ($11.11 per share for common stock).
• The acquisition includes Pre-Funded Warrants, providing flexibility for future exercise while managing beneficial ownership limits.

Risks

• The Pre-Funded Warrants carry a limitation on exercise if it would cause the holder's beneficial ownership to exceed 9.99% of the total shares of Common Stock, which could restrict immediate full exercise. This percentage may be increased or decreased at the option of the holder upon 61 days' prior notice, not to exceed 19.99%.

Future Outlook

NEA 17 and the other Reporting Persons may dispose of or acquire additional shares of Korro Bio, Inc. depending on market conditions, their continuing evaluation of the business and prospects of the Issuer, and other factors. There are no present plans for extraordinary corporate transactions, changes in management or board, material changes in capitalization or dividend policy, or other significant corporate structure alterations.

Management Comments

• NEA 17 acquired the NEA 17 Shares for investment purposes.

Industry Context

StockSavvy.ai notes that a significant investment by a prominent venture capital firm like New Enterprise Associates (NEA) in a biotechnology company such as Korro Bio, Inc. often signals a vote of confidence in the company's long-term potential and strategic direction. This type of institutional backing can be a positive indicator for the broader biotech sector, especially for companies focused on growth-oriented businesses, as it suggests continued investor appetite for innovative life science ventures.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.9% beneficial ownership stake by a major venture capital firm like NEA is a substantial position, often indicative of a lead investor or a significant participant in a financing round.
• While specific comparable companies or projects are not detailed in the filing, NEA's consistent investment strategy across various growth-oriented businesses, particularly in the healthcare and technology sectors, aligns with typical venture capital deployment patterns.
• The use of pre-funded warrants with beneficial ownership limitations is a common mechanism in private placements to allow large investors to participate without immediately triggering higher reporting thresholds or control implications.

Stakeholder Impact

• Shareholders: The capital raise could dilute existing shareholders, but also provides funding for company operations and growth. The investment by a reputable firm like NEA could be seen as a positive endorsement.
• Company (Korro Bio, Inc.): Receives capital for operations and growth from institutional investors.
• Investors (NEA): Increases their stake in Korro Bio, Inc. for investment purposes, potentially seeking future returns.

Next Steps

• NEA 17 and other Reporting Persons may acquire or dispose of additional shares in the future, depending on market conditions and evaluation of Korro Bio, Inc.'s business.
• The Pre-Funded Warrants are exercisable at the option of the holder at any time after issuance, subject to beneficial ownership limitations.

Key Dates

Recommendation

The filing indicates a significant institutional investment in Korro Bio, Inc. through a private placement, which is generally a positive signal of investor confidence and provides capital to the company. However, as a Schedule 13D, it primarily reports a change in beneficial ownership rather than new operational or financial performance data. While the investment is a good sign, it doesn't provide enough new information to warrant a 'buy' or 'sell' recommendation without further analysis of Korro Bio, Inc.'s fundamentals and market valuation. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting more comprehensive financial or operational updates.

Keywords

Korro Bio, NEA, New Enterprise Associates, Schedule 13D, beneficial ownership, private placement, common stock, pre-funded warrants, investment, biotechnology, pharmaceuticals, equity investment, venture capital